Literature DB >> 12891668

Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred.

Pau Pastor1, Catherine M Roe, Andrés Villegas, Gabriel Bedoya, Sumi Chakraverty, Gloria García, Victoria Tirado, Joanne Norton, Silvia Ríos, Maribel Martínez, Kenneth S Kosik, Francisco Lopera, Alison M Goate.   

Abstract

We previously have identified a large kindred from Colombia in which Alzheimer's disease (AD) is caused by the E280A presenilin 1 (PS1) mutation. The objective of this study was to examine whether environmental and genetic factors are responsible for variation in the phenotypic expression of the E280A PS1 mutation. We genotyped coding and promoter polymorphisms of the APOE gene in carriers of the E280A PS1 mutation. Kaplan-Meier product-limit and Cox proportional hazard models were used in the statistical analyses. DNA was available from 114 carriers of the E280A PS1 mutation, including 52 subjects with AD. APOE epsilon 4 allele carriers were more likely to develop AD at an earlier age than subjects without the epsilon 4 allele (hazard ratio, 2.07; 95% confidence interval, 1.07-3.99; p = 0.030). Subjects with low education were more likely to develop AD later than those with higher education (hazard ratio, 0.476; 95% confidence interval, 0.26-0.87). Low educational level was associated with rural residence (p < 0.001). Promoter APOE variants did not influence either the onset or the duration of the disease. This study is the first to our knowledge to demonstrate that genetic and environmental factors influence age of onset in a kindred with a familial AD mutation. Ann Neurol 2003

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12891668     DOI: 10.1002/ana.10636

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  87 in total

1.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

2.  Estimation and visualization of identity-by-descent within pedigrees simplifies interpretation of complex trait analysis.

Authors:  Elizabeth E Marchani; Ellen M Wijsman
Journal:  Hum Hered       Date:  2011-12-23       Impact factor: 0.444

3.  Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2.

Authors:  Suman Jayadev; James B Leverenz; Ellen Steinbart; Justin Stahl; William Klunk; Cheng-En Yu; Thomas D Bird
Journal:  Brain       Date:  2010-04       Impact factor: 13.501

Review 4.  Regional research priorities in brain and nervous system disorders.

Authors:  Vijayalakshmi Ravindranath; Hoang-Minh Dang; Rodolfo G Goya; Hader Mansour; Vishwajit L Nimgaonkar; Vivienne Ann Russell; Yu Xin
Journal:  Nature       Date:  2015-11-19       Impact factor: 49.962

5.  The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.

Authors:  Bruno A Benitez; Celeste M Karch; Yefei Cai; Sheng Chih Jin; Breanna Cooper; David Carrell; Sarah Bertelsen; Lori Chibnik; Julie A Schneider; David A Bennett; Anne M Fagan; David Holtzman; John C Morris; Alison M Goate; Carlos Cruchaga
Journal:  PLoS Genet       Date:  2013-08-22       Impact factor: 5.917

6.  Neuropsychological function in nondemented carriers of presenilin-1 mutations.

Authors:  J M Ringman; C Diaz-Olavarrieta; Y Rodriguez; M Chavez; L Fairbanks; F Paz; A Varpetian; H C Maldonado; M A Macias-Islas; J Murrell; B Ghetti; C Kawas
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

7.  Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset PSEN2 families.

Authors:  Elizabeth E Marchani; Thomas D Bird; Ellen J Steinbart; Elisabeth Rosenthal; Chang-En Yu; Gerard D Schellenberg; Ellen M Wijsman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-07       Impact factor: 3.568

8.  Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease.

Authors:  Isabelle Bos; Stephanie J B Vos; Suzanne E Schindler; Jason Hassenstab; Chengjie Xiong; Elizabeth Grant; Frans Verhey; John C Morris; Pieter Jelle Visser; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2019-08-01       Impact factor: 21.566

9.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Authors:  Nigel J Cairns; Milos D Ikonomovic; Tammie Benzinger; Martha Storandt; Anne M Fagan; Aarti R Shah; Lisa Taylor Reinwald; Deborah Carter; Angela Felton; David M Holtzman; Mark A Mintun; William E Klunk; John C Morris
Journal:  Arch Neurol       Date:  2009-12

10.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Authors:  John C Morris; Catherine M Roe; Elizabeth A Grant; Denise Head; Martha Storandt; Alison M Goate; Anne M Fagan; David M Holtzman; Mark A Mintun
Journal:  Arch Neurol       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.